Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2021-10-18 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science obtient l’autorisation de l’ANSM d’initier une étude avec la molécule AB8939 dans le traitement de la leucémie myéloïde aigue (LMA)
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has received authorization from the ANSM (French health authority) to initiate a clinical study (Phase I/II) for a new molecule (AB8939) in treating Acute Myeloid Leukemia (AML). This type of announcement, detailing regulatory milestones, clinical trial initiation, and scientific rationale, is characteristic of corporate communications aimed at investors and the public regarding ongoing drug development. It is not a full financial report (10-K, IR), a transcript (CT), or a formal voting result (DVA). Since it is a specific announcement about a regulatory/clinical development milestone, it fits best under the general category for regulatory announcements or news releases that don't fit other specific categories. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing regulatory/clinical progress, although 'LTR' (Legal Proceedings Report) is sometimes used for regulatory actions, this is a positive regulatory approval for a trial, making RNS a better fit as a general regulatory news item.
2021-10-18 French
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces regulatory authorization from the French Health Authority (ANSM) to initiate a clinical study (Phase I/II) for a drug candidate (AB8939) in treating AML. This type of announcement, detailing clinical trial progress, regulatory milestones, and scientific background, is characteristic of an update intended for investors and the public regarding ongoing operations, but it is not a formal periodic financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). Since it is a specific operational/clinical update that doesn't fit the other specialized categories (like DIRS, DIV, MANG), it falls best under the general category for regulatory or significant operational announcements that are not explicitly defined elsewhere. Given the options, 'Regulatory Filings' (RNS) serves as the best fit for a press release detailing a regulatory approval for a clinical trial, as it is a significant, non-financial regulatory event announcement.
2021-10-18 English
AB Science reçoit l’autorisation de la FDA pour initier le programme de développement clinique du masitinib dans le syndrome d’activation des mastocytes (MCAS)
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a significant corporate event: AB Science receiving FDA authorization to initiate a clinical development program for Masitinib in Mast Cell Activation Syndrome (MCAS). This type of announcement, detailing regulatory milestones, clinical trial initiation, and providing context/quotes, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific shareholder vote result (DVA), the most appropriate classification for a major, time-sensitive corporate/regulatory update that is not a full financial filing is Earnings Release (ER), as these press releases often accompany or precede formal earnings reports, or function as the primary means of disseminating material, non-financial news to the market quickly. Given the focus on FDA approval and clinical trial initiation, it is a material event announcement. While 'RNS' (Regulatory Filings) is a fallback, 'ER' often covers significant operational/regulatory news releases from pharmaceutical companies.
2021-10-04 French
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
Regulatory Filings Classification · 1% confidence The document is clearly labeled as a "PRESS RELEASE" and announces a significant corporate event: receiving FDA authorization to start a clinical development program for masitinib in MCAS. This type of announcement, detailing regulatory milestones, clinical trial initiation, and scientific rationale, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing a specific regulatory/clinical development milestone rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), it fits best under the 'Earnings Release' category if it contains key financial highlights, or 'Regulatory Filings' if it's purely operational/regulatory news. Given the focus is entirely on FDA approval and clinical trial plans, and it is not a standard quarterly financial report, it is most accurately classified as a general regulatory announcement or a specific operational update. Since there is no specific category for 'Clinical Trial/Regulatory Milestone Announcement' other than the broad 'RNS', and it is not a formal financial report, 'RNS' is the most appropriate fallback. However, press releases announcing key operational news often overlap with 'ER' if they are issued outside of standard earnings windows. Given the content is purely operational/regulatory news (FDA approval), 'RNS' (Regulatory Filings) is the safest general classification for non-financial, non-meeting related announcements that aren't covered elsewhere. It is not short enough to trigger the RPA rule, as it is a detailed announcement, not just a notice of publication.
2021-10-04 English
AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2021 (H1 2021). It contains detailed consolidated financial statements, including income statements and balance sheets, as well as management's analysis of financial results, clinical development updates, and corporate governance changes. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2021
2021-09-30 English
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2021 et présente un point sur ses activités
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2021 (interim period). It contains detailed financial statements, including a consolidated income statement and balance sheet, as well as management's analysis of the financial results, clinical development updates, and corporate events. It is not merely an announcement of a report, but the report itself, containing substantive financial data. H1 2021
2021-09-30 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.